Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy.

Radiat Oncol · 2015 · PMC4636817 · PMID 26545871

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an encouraging trendno p-value reported

Conclusion The use of RapidArc technology to improve the OAR sparing associated with a SIB of 1.65 and 2.12Gy/fraction in 33 fractions showed a good toxicity profile and an encouraging trend for overall survival and disease free survival for patients with advanced stage III-IV HNC.

also in 355 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.